Skip to content

Study · Systematic review · 2026

7 results

Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.

Stogios N, Agarwal SM, Maksyutynska K, Faisal H, Pless LL, Pillinger T, Humber B, Taylor VH, Remington G, Faulkner GEJ, Hahn MK

JAMA psychiatry1 Sept 2026

PMID42418179 (opens in a new tab)DOI10.1001/jamapsychiatry.2026.1814 (opens in a new tab)PepBankPUB-42418179
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In antipsychotic-treated patients with schizophrenia spectrum disorders, semaglutide reduced body weight versus placebo (MD -10.98 kg, 95% CI -13.33 to -8.62).

    In plain wordsIn antipsychotic-treated patients with schizophrenia-spectrum disorders, semaglutide was linked to greater weight reduction than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference
    −10.98 kg
    semaglutide versus placebo; 95% CI -13.33 to -8.62

    Source sentences

    Summary
    semaglutide (mean difference [MD], -10.98 kg; 95% CI, -13.33 to -8.62; k = 3; moderate certainty)
    6 context sentences
    Summary · context
    were associated with the most significant reductions in body weight compared to placebo.
    Summary · context
    Ovid MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) Search Portal were searched up to December 5, 2025.
    Summary · context
    Randomized clinical trials examining any pharmacological intervention for weight reduction in antipsychotic-treated patients with SSDs were included.
    Summary · context
    A systematic review and frequentist random-effects network meta-analysis was conducted.
    Summary · context
    A total of 95 studies examining 39 individual pharmacological interventions were included in this review (pooled N = 5898).
    Summary · context
    The primary outcome was change in body weight following treatment with pharmacological agent vs placebo or standard care.
  2. 02HumanSystematic reviewEfficacy outcome

    In antipsychotic-treated patients with schizophrenia spectrum disorders, liraglutide reduced body weight versus placebo (MD -5.43 kg, 95% CI -8.54 to -2.33).

    In plain wordsIn antipsychotic-treated patients with schizophrenia-spectrum disorders, liraglutide was linked to greater weight reduction than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference
    −5.43 kg
    liraglutide versus placebo; 95% CI -8.54 to -2.33

    Source sentences

    Summary
    liraglutide (MD, -5.43 kg; 95% CI, -8.54 to -2.33; k = 2; moderate certainty)
    6 context sentences
    Summary · context
    were associated with the most significant reductions in body weight compared to placebo.
    Summary · context
    Ovid MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) Search Portal were searched up to December 5, 2025.
    Summary · context
    Randomized clinical trials examining any pharmacological intervention for weight reduction in antipsychotic-treated patients with SSDs were included.
    Summary · context
    A systematic review and frequentist random-effects network meta-analysis was conducted.
    Summary · context
    A total of 95 studies examining 39 individual pharmacological interventions were included in this review (pooled N = 5898).
    Summary · context
    The primary outcome was change in body weight following treatment with pharmacological agent vs placebo or standard care.
  3. 03HumanSystematic reviewEfficacy outcome

    In antipsychotic-treated patients with schizophrenia-spectrum disorders, the network meta-analysis observed clinically meaningful weight change of at least 5% with semaglutide; no comparator for this threshold result was specified.

    In plain wordsIn antipsychotic-treated patients with schizophrenia-spectrum disorders, semaglutide showed clinically meaningful weight change of at least 5%; its comparator was unspecified.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedClinically meaningful weight change of at least 5%
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    weight change
    ≥ 5%
    semaglutide

    Source sentences

    Summary
    Clinically meaningful weight change of 5% or greater was observed with semaglutide and metformin.
    5 context sentences
    Summary · context
    Ovid MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) Search Portal were searched up to December 5, 2025.
    Summary · context
    Randomized clinical trials examining any pharmacological intervention for weight reduction in antipsychotic-treated patients with SSDs were included.
    Summary · context
    A systematic review and frequentist random-effects network meta-analysis was conducted.
    Summary · context
    A total of 95 studies examining 39 individual pharmacological interventions were included in this review (pooled N = 5898).
    Summary · context
    The primary outcome was change in body weight following treatment with pharmacological agent vs placebo or standard care.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 04HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In antipsychotic-treated patients with schizophrenia-spectrum disorders, the pooled interventions including semaglutide raised no major concerns about gastrointestinal adverse effects between interventions.

    In plain wordsIn antipsychotic-treated patients with schizophrenia-spectrum disorders, pooled interventions including semaglutide raised no major concerns about stomach or bowel side effects between interventions.

    Peptide
    Semaglutide
    Outcome
    Not applicableGastrointestinal adverse effects
    Study

    n: not reported in source

    Comparator
    Between interventions
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Beneficial effects on other metabolic outcomes were also noted with several of the medications, and there were no major concerns with gastrointestinal adverse effects or leaving the study early (ie, dropouts) between interventions.
    5 context sentences
    Summary · context
    Ovid MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) Search Portal were searched up to December 5, 2025.
    Summary · context
    Randomized clinical trials examining any pharmacological intervention for weight reduction in antipsychotic-treated patients with SSDs were included.
    Summary · context
    A systematic review and frequentist random-effects network meta-analysis was conducted.
    Summary · context
    A total of 95 studies examining 39 individual pharmacological interventions were included in this review (pooled N = 5898).
    Summary · context
    semaglutide (mean difference [MD], -10.98 kg; 95% CI, -13.33 to -8.62; k = 3; moderate certainty)

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In antipsychotic-treated patients with schizophrenia-spectrum disorders, the pooled interventions including liraglutide raised no major concerns about gastrointestinal adverse effects between interventions.

    In plain wordsIn antipsychotic-treated patients with schizophrenia-spectrum disorders, pooled interventions including liraglutide raised no major concerns about stomach or bowel side effects between interventions.

    Peptide
    Liraglutide
    Outcome
    Not applicableGastrointestinal adverse effects
    Study

    n: not reported in source

    Comparator
    Between interventions
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Beneficial effects on other metabolic outcomes were also noted with several of the medications, and there were no major concerns with gastrointestinal adverse effects or leaving the study early (ie, dropouts) between interventions.
    5 context sentences
    Summary · context
    Ovid MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) Search Portal were searched up to December 5, 2025.
    Summary · context
    Randomized clinical trials examining any pharmacological intervention for weight reduction in antipsychotic-treated patients with SSDs were included.
    Summary · context
    A systematic review and frequentist random-effects network meta-analysis was conducted.
    Summary · context
    A total of 95 studies examining 39 individual pharmacological interventions were included in this review (pooled N = 5898).
    Summary · context
    liraglutide (MD, -5.43 kg; 95% CI, -8.54 to -2.33; k = 2; moderate certainty)

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 06HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In antipsychotic-treated patients with schizophrenia-spectrum disorders, the pooled interventions including semaglutide raised no major concerns about study dropout between interventions.

    In plain wordsIn antipsychotic-treated patients with schizophrenia-spectrum disorders, pooled interventions including semaglutide raised no major concerns about leaving the study early between interventions.

    Peptide
    Semaglutide
    Outcome
    Not applicableStudy dropout
    Study

    n: not reported in source

    Comparator
    Between interventions
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Beneficial effects on other metabolic outcomes were also noted with several of the medications, and there were no major concerns with gastrointestinal adverse effects or leaving the study early (ie, dropouts) between interventions.
    5 context sentences
    Summary · context
    Ovid MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) Search Portal were searched up to December 5, 2025.
    Summary · context
    Randomized clinical trials examining any pharmacological intervention for weight reduction in antipsychotic-treated patients with SSDs were included.
    Summary · context
    A systematic review and frequentist random-effects network meta-analysis was conducted.
    Summary · context
    A total of 95 studies examining 39 individual pharmacological interventions were included in this review (pooled N = 5898).
    Summary · context
    semaglutide (mean difference [MD], -10.98 kg; 95% CI, -13.33 to -8.62; k = 3; moderate certainty)

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In antipsychotic-treated patients with schizophrenia-spectrum disorders, the pooled interventions including liraglutide raised no major concerns about study dropout between interventions.

    In plain wordsIn antipsychotic-treated patients with schizophrenia-spectrum disorders, pooled interventions including liraglutide raised no major concerns about leaving the study early between interventions.

    Peptide
    Liraglutide
    Outcome
    Not applicableStudy dropout
    Study

    n: not reported in source

    Comparator
    Between interventions
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Beneficial effects on other metabolic outcomes were also noted with several of the medications, and there were no major concerns with gastrointestinal adverse effects or leaving the study early (ie, dropouts) between interventions.
    5 context sentences
    Summary · context
    Ovid MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) Search Portal were searched up to December 5, 2025.
    Summary · context
    Randomized clinical trials examining any pharmacological intervention for weight reduction in antipsychotic-treated patients with SSDs were included.
    Summary · context
    A systematic review and frequentist random-effects network meta-analysis was conducted.
    Summary · context
    A total of 95 studies examining 39 individual pharmacological interventions were included in this review (pooled N = 5898).
    Summary · context
    liraglutide (MD, -5.43 kg; 95% CI, -8.54 to -2.33; k = 2; moderate certainty)

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.